Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 5, Issue 3, 2004, Pages 114-120

  Madrid, Antonio H ^a   Marín Marín, Irene ^a   Cervantes, Carlos Escobar ^a   Morell, Enrique Bernal ^a   Estévez, Jaime Escudero ^a   Moreno, Gerardo ^a   Parajón, Jorge Rondón ^a   Peng, Jian ^a   Limón, Lilianna ^a   Nannini, Sebastian ^a   Moro, Concepción ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Angiotensin; Cardioversion; Fibrillation; Tachyarrhythmias

Indexed keywords

ACENOCOUMAROL; AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; IRBESARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BRADYCARDIA; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOSE RESPONSE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART DISEASE; HUMAN; HYPOTHYROIDISM; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; RECURRENCE RISK; RECURRENT DISEASE; RISK ASSESSMENT; SKIN TOXICITY;

EID: 6444219596     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2004.027     Document Type: Article

References (28)

1. Madrid AH, Bueno MG, Rebollo JM et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. A prospective and randomized study. Circulation 2002;106:331-6.
2. Nakashima H, Kumagai K, Urata H et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000;101:2612-17.
3. Pedersen OD, Bagger H, Køber L et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376-80.
4. Vermes E, Tardif J, Bourassa M et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction. Insight from the studies of left ventricular dysfunction (SOLVD) trials. Circulation 2003;107:2926-31.
5. Chen Y, Chen Y, Chan P et al. Angiotensin II increases the arrhythmogenic activity of pulmonary vein cardiomyocyte. PACE 2003;26:632.
6. Belluzzi F, Sernesi L, Valenti C et al. Angiotensin-converting enzyme inhibition with trandolapril prevents recurrence of paroxysmal lone atrial fibrillation in normotensive patients. Eur Heart J 2003;24:2162.
7. Kumagai K, Nakashima H, Urata H et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodelling in atrial fibrillation. J Am Coll Cardiol 2003; 41 2197-204.
8. Everett TH, Li H, Mangrum JM et al. Electrical, morphological, and ultrastructural remodelling and reverse remodelling in a canine model of chronic atrial fibrillation. Circulation 2000; 102:1454-60.
9. Allessie MA. Atrial electrophysiological remodeling: another vicious circle? J Cardiovasc Electrophysiol 1998;9: 1378-93.
10. López B, Querejeta R, Varo N et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001;104:286-91.
11. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 Diabetes. N Engl J Med 2001;345: 870-8.
12. Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
13. Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40.
14. Kwo-Chang U, Tsung Po T, Wen-Chung Y et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Eur Heart J 2003;24:2090-8.
15. Heidbüchel H. A paradigm shift in treatment for atrial fibrillation: from electrical to structural therapy? Eur Heart J 2003;24:2077-8.
16. Madrid AH, Escobar C, Rebollo JM et al. Angiotensin receptor blocker as adjunctive therapy for rhythm control in atrial fibrillation: results of the irbesartan - amiodarone trial. Card Electrophysiol Rev 2003;7:243-6.
17. Ihara M, Urata H, Shirai K et al. High cardiac angiotensin-II-forming activity in infarcted and non-infarcted human myocardium. Cardiology 2000;94:247-53.
18. Verdecchia P, Reboldi G, Gattobigio R et al. Atrial fibrillation in hypertension; predictors and outcome. Hypertension 2003;41:218-23.
19. Healey JS, Connolly SJ. Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. Am J Cardiol 2003;91(10A):9G-14G.
20. Dorian P, Mangat I. Restoring sinus rhythm in atrial fibrillation. A pyrrhic victory? J Am Coll Cardiol 2003;42 30-2.
21. Klein H, Goette A. Blockade of atrial angiotensin II type 1 receptors. A novel antiarrhythmic strategy to prevent atrial fibrillation. J Am Coll Cardiol 2003;41:2205-06.
22. Li D, Fareh S, Leung TK et al. Promotion of atrial fibrillation by heart failure in dogs: atrial remodelling of a different sort. Circulation 1999;100:87-95.
23. Malmquist K, Ohman KP, Lind L et al. Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol. J Cardiovasc Pharmacol 2003;42:719-26.
24. Caballero R, Delpón E, Valenzuela C et al. Losartan and its metabolite E3174 modify cardiac delayed rectifier K+ currents. Circulation 2002;101:1199-205.
25. Moreno I, Caballero R, Gonzalez T et al. Effects of irbesartan on cloned potassium channels involved in human cardiac repolarization. J Pharmacol Exp Ther 2003;304:862-73.
26. Haissaguerre M, Jais P, Shah DC et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-66.
27. Wijffels M, Crijms H. Recent advances in drug therapy for atrial fibrillation. J Cardiovasc Electrophysiol 2003;14 540-47.
28. Tamargo J, Caballero R, Delpón E. Pharmacological approaches in the treatment of atrial fibrillation. Curr Med Chem 2004;11:13-28.